Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

The aim of this study was to determine the effects of micronized fenofibrate (160 mg/daily) on:

• Fasting and postprandial lipids and lipoproteins after a standarized test meal.
• Fasting and postprandial oxidized fatty acids and oxidized low density lipoprotein after a standarized test meal.
• Fasting and postprandial inflammatory mediators after a standarized test meal.
• Fasting and postprandial lipopolysaccharide-stimulated cytokine production after a standarized test meal.
• Fasting and postprandial markers of hemostasis, fibrinolysis and blood viscosity after a standarized test meal.

Inclusion criteria

• males and postmenopausal females 18 years of age with fasting triglycerides greater than or equal to 1.7 mmol/L and <6.9 mmol/L
• two or more of the following Adult Treatment Panel III (1) criteria of the metabolic syndrome: abdominal obesity (waist circumference >89 cm in females and >102 cm in males); low high-density lipoprotein cholesterol (HDL-C) (<1.3 mmol/L in women and <1.0 mmol/L in men); hypertension (systolic blood pressure >130 or diastolic blood pressure >85 mm Hg) or current drug therapy for hypertension; and impaired fasting glucose (between 6.1 mmol/L and 7.0 mmol/L).

Exclusion criteria

• included types 1 or 2 diabetes
• Body mass index >40 kg/m2
• Use of lipid-lowering therapies
• Oral hypoglycemic therapies
• Insulin
• Aspirin >81 mg daily
• Regular use of non-steroidal anti-inflammatory agents or cyclooxygenase-2 inhibitors, corticosteroids (oral and inhaled), anti-oxidants (including multivitamins), herbal or fiber supplements recent changes in type or formulation of hormone replacement therapy (in the last 6 months)
• Alcohol intake >3 drinks per day
• Untreated hypothyroidism or recent change (within 2 months) of thyroid replacement therapy
• Cigarette smoking (current or within the last 6 months)